{"id":"W4394896461","doi":"10.1177/17562864241243186","title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Neurological Disorders","topic":"Myasthenia Gravis and Thymoma","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Chugai Pharmaceutical; Horizon Therapeutics; Genentech; Grifols; Mitsubishi Tanabe Pharma Corporation; Warszawski Uniwersytet Medyczny; CSL Behring; National Institute for Health and Care Research; Regeneron Pharmaceuticals; National Institutes of Health; UCB Pharma; Argenx; Cytokinetics; Japan Blood Products Organization; Union Chimique Belge; Alexion Pharmaceuticals; Patient-Centered Outcomes Research Institute; Biogen; Centers for Disease Control and Prevention; Muscular Dystrophy Association; Uniwersytet Warszawski; Momenta Pharmaceuticals; Sanofi; AstraZeneca; Myasthenia Gravis Foundation of America","keywords":"Medicine; Myasthenia gravis; Interim; Interim analysis; Open label; Term (time); Extension (predicate logic); Adverse effect; Clinical trial; Internal medicine; Law; Computer science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005684379,0.0008966543,0.002084227,0.0003028103,0.0003546123,0.001038587,0.0004577808,0.0009342022,0.001862286],"category_scores_gemma":[0.002648648,0.0003200413,0.002496261,0.0002932624,0.0005730964,0.0007756719,0.0003870647,0.002218847,0.0005260321],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004784265,"about_ca_system_score_gemma":0.0007127835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002293041,"about_ca_topic_score_gemma":0.000396307,"domain_scores_codex":[0.9987279,0.0006505533,0.00008235847,0.0001538963,0.0001759105,0.0002093705],"domain_scores_gemma":[0.9974733,0.0006914719,0.0008172031,0.0004106738,0.0001685238,0.0004387555],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.871237,0.01102989,0.03795582,0.0003897656,0.003114154,0.0003233093,0.0001966498,0.001867916,0.0160472,0.0001485369,0.001605686,0.05608408],"study_design_scores_gemma":[0.3269103,0.473696,0.1819569,0.00006758914,0.005091327,0.0005293002,0.0001025323,0.002884594,0.005471156,0.0003625881,0.002858564,0.0000691129],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945915,0.001437753,0.0008315084,0.0001497365,0.0000438086,0.0007504907,0.001106208,0.00005894681,0.001030146],"genre_scores_gemma":[0.9946697,0.0003818835,0.0008830855,0.0003243879,0.00008605906,0.0007044635,0.002064765,0.00001431654,0.0008713045],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005684379,"threshold_uncertainty_score":0.0300622,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02397615723265628,"score_gpt":0.329973967553128,"score_spread":0.3059978103204717,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}